Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2020
Q4 GAAP revenue including Grant Revenue
“Responding to the pandemic crisis as well as advances in therapies to treat Alzheimer’s has accelerated our leadership of precision health and the proteomics revolution,” said Chairman, Chief Executive Officer and President,
Fourth Quarter 2020 Financial Highlights
Key financial results for the four quarter of 2020 are shown below:
-
Q4 GAAP total revenue, which includes Grant Revenue, was
$26.1M versus prior year Q4 of$15.9M ; -
Q4 non-GAAP total revenue was
$21.6M versus prior year Q4 of$15.9M , an increase of 36%; -
Q4 GAAP product revenue was
$15.7M versus prior year Q4 of$11.4M , an increase of 38%; -
Q4 GAAP service and other revenue was
$5.5M versus prior year Q4 of$4.3M , an increase of 28%
Full Year 2020 Financial Highlights
Key financial results for FY 2020 are shown below:
-
FY GAAP total revenue, which includes one-time License Revenue and Grant Revenue, was
$86.4M versus prior year FY of$56.7M ; -
FY non-GAAP total revenue was
$68.8M versus prior year FY of$56.7M , an increase of 21%; -
FY GAAP product revenue was
$44.0M versus prior year FY of$40.5M , an increase of 9%; -
FY GAAP service and other revenue was
$24.1M versus prior year FY of$16.1M , an increase of 50%
For additional information on the non-GAAP financial measures included in this press release, please see “Use of Non-GAAP Financial Measures” and “Reconciliation of Non-GAAP Financials” below.
Fourth Quarter and Full Year Business Highlights
-
Awarded an
$18.2M contract with theNIH through its RADx initiative to accelerate the continued development and scale-up of a novel SARS-CoV-2 antigen test. - Received FDA Emergency Use Authorizations for novel SARS-CoV-2 antigen test (after year-end) and for semi-quantitative antibody test, underscoring our longstanding science-first mentality and deep dedication to the highest standards of quality and scientific rigor across our business.
-
Leveraging the unparalleled ultra-sensitivity of Simoa, enabled several leading researchers globally, including at the
NIH , to begin tackling leading-edge COVID challenges, such as establishing potential for blood based anti-viral endpoints for new drug therapies and understanding the long-term complications of COVID-19. - Expanded our differentiated Neurology menu to include tau phosphorylated at threonine 181 (pTau-181), a highly specific biomarker for the study of Alzheimer’s disease pathology, in cerebral spinal fluid (CSF), serum and plasma as well as launched Neuro Multiplex assays associated with many neurodegenerative diseases. Our biomarker portfolio is now supporting leading Alzheimer’s programs globally and a growing body of research, including work published recently in The Lancet Neurology. This work suggests that blood pTau-181 levels could prove critical to predicting Alzheimer’s disease progression and differentiating the disease from other neurodegenerative disorders, marking a critical step toward AD early detection, clinical trial advancements, improved patient triaging and asymptomatic screening.
- Novartis’ multiple sclerosis (MS) drug KESIMPTA® (ofatumumab), which utilized Nf-L as secondary endpoint, was approved by the FDA.
-
Quanterix’ Simoa technology was highlighted in a record 443 new publications in 2020, bringing total Simoa-specific inclusions to over 1,120. Also, was invited to present at several marquis symposiums showcasing our
Precision Health vision and potential to catalyze asymptomatic medicine. - Instrument installed base increased by 34% in 2020 to 535, despite access challenges posed by COVID-19. This includes 93 HD-X placements with over 50% new installations and 84 new SR-X and SP-X placements.
- Solidified Simoa’s technological leadership by achieving a 100x sensitivity improvement in a pilot of the digital enzyme-linked immunosorbent assay (ELISA) that powers the Company’s HD-X™ and SR-X™ Ultra-Sensitive Biomarker Detection Systems.
-
Entered into a non-exclusive royalty-bearing license agreement with Abbott Laboratories, to grant
Abbott access to Quanterix’ portfolio of bead-based technology patents for use in in-vitro diagnostic (IVD) applications. - Realized multi-category revenue opportunities with one of the largest multi-national, healthcare payor groups, with execution of multiple population surveillance studies, creating beachhead for our vision for the future of precision medicine, where early and non-invasive disease detection has the potential to transform life and healthcare costs.
-
Successfully raised
~$385 million in gross proceeds across 2020 and early-2021 through our follow-on offerings, further strengthening our balance sheet with growth capital. -
William Geist joinedQuanterix as Chief Operating Officer to help us sustain and grown our strong momentum across numerous digital biomarker platforms.
Conference Call
In conjunction with this announcement,
Financial Highlights
|
Quanterix Income Statement |
|
|
|
|
|
|
|
|
|
|
|
|
|
in ' |
Q4 2020 |
Q4 2019 |
YTD 2020 |
YTD 2019 |
|
|
Product Revenue |
15,732 |
11,431 |
44,017 |
40,491 |
|
|
Service and Other Revenue |
5,498 |
4,302 |
24,129 |
16,059 |
|
|
Collaboration and License Revenue |
408 |
184 |
11,809 |
184 |
|
|
Development Revenue |
4,493 |
0 |
6,422 |
0 |
|
|
Total Revenue |
26,131 |
15,917 |
86,377 |
56,734 |
|
|
|
|
||||
|
Cost of Product Revenue |
7,961 |
6,684 |
25,950 |
20,900 |
|
|
Cost of Services Revenue |
3,120 |
2,368 |
11,245 |
8,998 |
|
|
Cost of License Revenue |
0 |
0 |
1,000 |
0 |
|
|
Gross Profit |
15,050 |
6,865 |
48,182 |
26,836 |
|
|
Gross Margin % |
57.6% |
43.1% |
55.8% |
47.3% |
|
|
|
|
||||
|
Research and Development |
6,217 |
4,398 |
20,174 |
16,190 |
|
|
Selling, General and Administrative |
18,766 |
13,953 |
59,592 |
52,246 |
|
|
Total Operating Expenses |
24,983 |
18,351 |
79,766 |
68,436 |
|
|
|
|
||||
|
Loss From Operations |
-9,933 |
-11,486 |
-31,584 |
-41,600 |
|
|
Interest Income (Expense), net |
-166 |
282 |
-273 |
627 |
|
|
Other Income (Expense), net |
155 |
139 |
-49 |
-10 |
|
|
Tax |
123 |
107 |
376 |
187 |
|
|
Net Loss |
|
-9,821 |
-10,958 |
-31,530 |
-40,796 |
Weighted average shares outstanding was 31.7 million for Q4 2020 and 28.6 million for YTD 2020
|
|
||
|
Quanterix Balance Sheet |
||
|
in ' |
At |
At |
|
Cash and Cash Equivalents |
181,584 |
109,155 |
|
Accounts Receivable |
17,184 |
10,906 |
|
Inventory |
14,856 |
10,463 |
|
Prepaid Expenses and Other |
5,981 |
2,137 |
|
Total Current Assets |
219,605 |
132,661 |
|
Restricted Cash |
1,000 |
1,026 |
|
Property and Equipment, Net |
13,912 |
12,047 |
|
Intangible Assets, Net |
13,716 |
14,307 |
|
|
10,460 |
9,353 |
|
Right-of-Use Assets |
11,995 |
0 |
|
Other Non-Current Assets |
357 |
557 |
|
Total Assets |
271,045 |
169,951 |
|
Accounts Payable & Accrued Expenses |
22,421 |
14,845 |
|
Deferred Revenue |
5,421 |
4,697 |
|
Current Portion of Long Term Debt |
7,673 |
75 |
|
Lease Liabilities |
1,234 |
0 |
|
Other Current Liabilities |
3,054 |
216 |
|
Total Current Liabilities |
39,803 |
19,833 |
|
Deferred Revenue, Net of Current Portion |
577 |
466 |
|
Long Term Debt, Net of Current Portion |
0 |
7,587 |
|
Lease Liabilities, Net of Current Portion |
21,891 |
0 |
|
Other Non-Current Liabilities |
2,649 |
13,407 |
|
Total Liabilities |
64,920 |
41,293 |
|
Total Stockholders’ Equity |
206,125 |
128,658 |
|
|
|
|
|
Total Liabilities and Stockholders’ Equity |
271,045 |
169,951 |
Use of Non-GAAP Financial Measures
To supplement the Company’s financial statements presented on a GAAP basis, the Company has provided certain non-GAAP financial measures, including non-GAAP revenue. Management uses these non-GAAP measures to evaluate the Company’s operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in its business. Management believes that such measures are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing the Company’s operating performance. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures set forth below.
| Reconciliation of non-GAAP Financials | ||||||||||||||
| (In thousands) | ||||||||||||||
|
2020 |
2019 |
|
2020 |
|
|
2019 |
|
|||||||
| Three months ended | Twelve months ended | |||||||||||||
| Total revenue |
$ |
26,131 |
|
$ |
15,917 |
|
$ |
86,377 |
|
$ |
56,734 |
|
||
| License agreement revenue (Note 1) |
|
— |
|
|
— |
|
$ |
(11,200 |
) |
|
— |
|
||
| Grant revenue (Note 2) |
$ |
(4,493 |
) |
|
— |
|
$ |
(6,422 |
) |
|
— |
|
||
| Non-GAAP revenue |
$ |
21,638 |
|
$ |
15,917 |
|
$ |
68,755 |
|
$ |
56,734 |
|
||
| Gross profit |
$ |
15,050 |
|
$ |
6,865 |
|
$ |
48,182 |
|
$ |
26,836 |
|
||
| License agreement revenue (Note 1) |
|
— |
|
|
— |
|
$ |
(11,200 |
) |
|
— |
|
||
| Grant revenue (Note 2) |
$ |
(4,493 |
) |
|
— |
|
$ |
(6,422 |
) |
|
— |
|
||
| Acquisition-related purchase accounting charges (Note 3) |
$ |
433 |
|
$ |
667 |
|
$ |
2,251 |
|
$ |
1,378 |
|
||
| Cost of license revenue (Note 4) |
|
— |
|
|
— |
|
$ |
1,000 |
|
|
— |
|
||
| Non-GAAP gross profit |
$ |
10,990 |
|
$ |
7,532 |
|
$ |
33,811 |
|
$ |
28,214 |
|
||
| GAAP gross margin % |
|
57.6 |
% |
|
43.1 |
% |
|
55.8 |
% |
|
47.3 |
% |
||
| Non-GAAP gross margin % |
|
50.8 |
% |
|
47.3 |
% |
|
49.2 |
% |
|
49.7 |
% |
||
| GAAP total operating expenses |
$ |
24,983 |
|
$ |
18,351 |
|
$ |
79,766 |
|
$ |
68,436 |
|
||
| Grant research and development expenses (Note 5) |
$ |
(2,322 |
) |
|
— |
|
$ |
(3,625 |
) |
|
— |
|
||
| Acquisition-related purchase accounting charges (Note 6) |
$ |
(20 |
) |
$ |
(20 |
) |
$ |
(81 |
) |
$ |
(41 |
) |
||
| Non-GAAP total operating expenses |
$ |
22,641 |
|
$ |
18,331 |
|
$ |
76,060 |
|
$ |
68,395 |
|
||
| GAAP loss from operations |
$ |
(9,933 |
) |
$ |
(11,486 |
) |
$ |
(31,584 |
) |
$ |
(41,600 |
) |
||
| Non-GAAP loss from operations |
$ |
(11,651 |
) |
$ |
(10,799 |
) |
$ |
(42,249 |
) |
$ |
(40,181 |
) |
||
| Note 1: During the twelve months ended |
||||||||||||||
| Note 2: During the three and twelve months ended |
||||||||||||||
| Note 3: During the three months ended |
||||||||||||||
| Note 4: During the twelve months ended |
||||||||||||||
| Note 5: During the three and twelve months ended |
||||||||||||||
| Note 6: During the three and twelve months ended |
||||||||||||||
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302006101/en/
Media
quanterix@pancomm.com
Investor Relations:
(774) 278-0496
shrusovsky@quanterix.com
Source: